Who
Craig B. Thompson
Director
Company insider
Files Form 4 as: Director, Charles River Laboratories International; Director, Regeneron Pharmaceuticals; Director, Merck & Company.
In numbers
- Trades disclosed
- 51
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 30 May 2008
- Last trade
- 8 May 2026
- Last filed
- 12 May 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 May 2026filed 12 May 2026 | CRL Charles River Laboratories InternationalLife-science tools | SEC FORM 4 Code A | $255K1,438 at $177.62 | filing |
| 8 May 2026filed 12 May 2026 | CRL Charles River Laboratories InternationalLife-science tools | SEC FORM 4 Code A | $255K1,438 at $177.62 | filing |
| 2 Jan 2026filed 6 Jan 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —155 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,962 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,962 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —155 at $0.00 | filing |
| 21 May 2025filed 23 May 2025 | CRL Charles River Laboratories Internationaloption or derivative · Life-science tools | SEC FORM 4 Code A | $280K2,076 at $134.98 | filing |
| 21 May 2025filed 23 May 2025 | CRL Charles River Laboratories InternationalLife-science tools | SEC FORM 4 Code A | $128K946 at $134.98 | filing |
| 2 Jan 2025filed 6 Jan 2025 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,958 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —166 at $0.00 | filing |
| 13 May 2024filed 15 May 2024 | CRL Charles River Laboratories Internationaloption or derivative · Life-science tools | SEC FORM 4 Code A | $299K1,311 at $228.41 | filing |
| 13 May 2024filed 15 May 2024 | CRL Charles River Laboratories InternationalLife-science tools | SEC FORM 4 Code A | $128K559 at $228.41 | filing |
| 2 Jan 2024filed 4 Jan 2024 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,607 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —135 at $0.00 | filing |
| 15 May 2023filed 17 May 2023 | CRL Charles River Laboratories Internationaloption or derivative · Life-science tools | SEC FORM 4 Code A | $321K1,669 at $192.36 | filing |
| 15 May 2023filed 17 May 2023 | CRL Charles River Laboratories InternationalLife-science tools | SEC FORM 4 Code A | —664 at $0.00 | filing |
| 3 Jan 2023filed 5 Jan 2023 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —477 at $0.00 | filing |
| 3 Jan 2023filed 5 Jan 2023 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —40 at $0.00 | filing |
| 3 Jan 2023filed 4 Jan 2023 | CRL Charles River Laboratories Internationaloption or derivative · Life-science tools | SEC FORM 4 Code A | $129K592 at $218.40 | filing |
| 3 Jan 2023filed 4 Jan 2023 | CRL Charles River Laboratories InternationalLife-science tools | SEC FORM 4 Code A | —244 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.